Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

FOLD - Amicus Therapeutics Inc


IEX Last Trade
11.605
0.305   2.628%

Share volume: 2,908,965
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$11.30
0.31
2.70%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
7%
Profitability 0%
Dept financing 22%
Liquidity 49%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
-1.28%
1 Month
15.18%
3 Months
17.51%
6 Months
-10.35%
1 Year
-11.71%
2 Year
2.83%
Key data
Stock price
$11.60
P/E Ratio 
-28.81
DAY RANGE
N/A - N/A
EPS 
-$0.40
52 WEEK RANGE
$9.02 - $14.57
52 WEEK CHANGE
-$0.10
MARKET CAP 
3.443 B
YIELD 
N/A
SHARES OUTSTANDING 
296.591 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
BETA 
1.29
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,159,681
AVERAGE 30 VOLUME 
$2,877,729
Company detail
CEO: John Crowley
Region: US
Website: http://www.amicusrx.com/
Employees: 886
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g

Recent news